Therapeutic options for advanced thyroid cancer
Open Access
- 9 September 2019
- journal article
- Published by Peertechz Publications Private Limited in International Journal of Clinical Endocrinology and Metabolism
- Vol. 5 (1), 026-034
- https://doi.org/10.17352/ijcem.000040
Abstract
No abstract availableThis publication has 99 references indexed in Scilit:
- Neoadjuvant Chemotherapy in 16 Patients with Locally Advanced Papillary Thyroid CarcinomaThyroid®, 2013
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialThe Lancet Oncology, 2012
- Neoadjuvant Chemotherapy in 29 Patients with Locally Advanced Follicular or Hürthle Cell Thyroid Carcinoma: A Phase 2 StudyThyroid®, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancerActa Endocrinologica, 2012
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid CarcinomaThyroid®, 2010
- Multikinase inhibitors in thyroid cancerEuropean Journal of Cancer, 2010
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009